Delphia (USA)’s Spyre Therapeutics SYRE Stock Holding History

Delphia (USA)’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-518	Closed	-$61K	–	402
2021 Q4	$61K	Buy	+518	New	+$81.8K	0.06%	263

Other funds holding SYRE

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Delphia (USA)'s SYRE Position: Q1 2022 in Review

Delphia (USA) sold out of Spyre Therapeutics (SYRE) in Q1 2022, closing a stake of 518 shares — an estimated $61K sold.

Delphia (USA) first reported a position in SYRE in Q4 2021 and held it in 1 quarter. The position peaked at $61K in Q4 2021. 83 funds tracked by Wall St. Rank hold SYRE as of Q1 2022.

Delphia (USA) reported no remaining Spyre Therapeutics position as of Q1 2022 after selling out during the quarter.
Delphia (USA) sold 518 Spyre Therapeutics shares in Q1 2022, an estimated $61K.
Delphia (USA) first reported a position in Spyre Therapeutics in Q4 2021 and held it in 1 quarter.
Delphia (USA)'s Spyre Therapeutics position peaked at $61K in Q4 2021.
83 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2022.

Based on Delphia (USA)'s 13F filing for Q1 2022, filed 16 May 2022.